HLA-E as an Emerging Checkpoint and Biomarker in Personalized Cancer Immunotherapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Human Leukocyte Antigen (HLA) molecules are critical for immune responses, distinguishing self from non-self.
• HLA class I molecules interact with T-cell receptors (TCRs) to activate T cells, crucial for adaptive immunity.
• HLA diversity influences the efficacy of cancer immunotherapies like checkpoint inhibitors and CAR-T-cell therapy.

Purpose of the Study:

• To review the role of Human Leukocyte Antigen E (HLA-E) in cancer immune evasion.
• To summarize recent advances in identifying HLA-E-restricted peptides.
• To evaluate current HLA-E-dependent and independent adoptive immunotherapies.

Main Methods:

• Literature review of studies on HLA-E expression and function in cancer.
• Analysis of HLA-E's interaction with Natural Killer (NK) cells and T-cell subsets.
• Evaluation of therapeutic strategies targeting HLA-E.

Main Results:

• HLA-E exhibits immunosuppressive properties, contributing to tumor immune escape.
• Tumor cell expression of HLA-E inhibits cytotoxic activity of NK and CD8+ T cells.
• Identifying HLA-E-restricted peptides is advancing immunotherapy development.

Conclusions:

• Understanding HLA-E's role in immune evasion provides insights for novel personalized cancer immunotherapies.
• Targeting HLA-E can potentially improve the effectiveness of existing cancer treatments.
• Modulating HLA-E presents a promising avenue for improving patient prognosis in various cancers.